NSI-189 vs Semax
A side-by-side research comparison of NSI-189 and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | NSI-189 | Semax |
|---|---|---|
| Full name | NSI-189 Phosphate (Neurogenic Compound) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Stimulates hippocampal neural stem cell proliferation and differentiation via Akt/CREB/BDNF signaling. Increases hippocampal volume visible on MRI. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | 366.4 Da | 813.9 Da |
| Half-life | 18-22 hours | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | High (oral) | Moderate (intranasal) |
| Typical dose | 40-80 mg | 200-600 mcg per dose |
| Frequency | Once daily | 2-3x daily |
| Route | Oral | Intranasal drops/spray |
NSI-189 reported benefits
- Hippocampal neurogenesis
- Measurable brain volume increase
- Cognitive enhancement
- Antidepressant effects
- Long-term neural benefit
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.